District court

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Luna Innovations Inc. (LUNA) Investors

Retrieved on: 
Tuesday, April 2, 2024
Form, District court, News, Luna Innovations, LUNA, Bank statement, Court, Cryptocurrency

Investors have until May 31, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 31, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On March 12, 2024, Luna Innovations filed with the U.S. Securities and Exchange Commission (“SEC”) a Current Report on Form 8-K announcing it would need to restate its financial statements for the second and third quarters of 2023.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors

Retrieved on: 
Tuesday, April 2, 2024
Sickle cell disease, AML, District court, Patient, History, News, FDA, Court, Pharmaceutical industry

Investors have until May 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The lawsuit alleges that Blue provided investors with false and misleading information in order to bolster investor expectations and share prices.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

LUNA INNOVATIONS INCORPORATED SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Luna Innovations Incorporated (NASDAQ: LUNA)

Retrieved on: 
Tuesday, April 2, 2024
District court, News, Luna Innovations, LUNA, Bank statement, Complaint, Defendant, Court, Advertising, Cryptocurrency

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Luna Innovations Incorporated (NASDAQ: LUNA)?
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Luna Innovations Incorporated (“Luna Innovations” or the “Company”) (NASDAQ: LUNA) between August 11, 2023 and March 25, 2024, inclusive (the “Class Period”).
  • If you purchased or acquired Luna Innovations securities, and/or would like to discuss your legal rights and options please visit Luna Innovations Incorporated Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • If you purchased or acquired Luna Innovations securities, and/or would like to discuss your legal rights and options please visit Luna Innovations Incorporated Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .

BLUEBIRD BIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (NASDAQ: BLUE)

Retrieved on: 
Tuesday, April 2, 2024
Sickle cell disease, Blue, District court, Patient, Food and Drug Administration, News, Cancer, Complaint, Action Replay, Food, FDA, Court, Advertising, Bluebird bio, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Luna Innovations Incorporated (LUNA)

Retrieved on: 
Tuesday, April 2, 2024
8-K, Committee, Form, District court, Defendant, News, LUNA, Bank statement, Complaint, Retirement, Person, Cryptocurrency

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Luna Innovations Incorporated (“Luna” or the “Company”) (NYSE: LUNA) securities between August 11, 2023 and March 25, 2024, inclusive (the “Class Period”).

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Luna Innovations Incorporated (“Luna” or the “Company”) (NYSE: LUNA) securities between August 11, 2023 and March 25, 2024, inclusive (the “Class Period”).
  • The lawsuit seeks to recover damages for the Company’s investors under the federal securities laws.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

AMPL STOCKHOLDER ALERT: Robbins LLP Reminds Investors of Quickly Approaching Lead Plaintiff Deadline – April 15, 2024 – in the Amplitude, Inc. Class Action

Retrieved on: 
Tuesday, April 2, 2024
Steps, Depression, Growth, Weakness, CFO, Acceleration, District court, News, IPO, Complaint, Court, Person, Cryptocurrency

The complaint seeks relief on behalf of the named plaintiff and all other similarly situated holders of Amplitude during the Class Period.

Key Points: 
  • The complaint seeks relief on behalf of the named plaintiff and all other similarly situated holders of Amplitude during the Class Period.
  • The named plaintiff is represented by Robbins LLP.
  • Founded in 2012, Amplitude is a technology company that helps businesses analyze data for their digital products and track customer interactions.
  • The price of Amplitude Class A stock currently trades at less than $15 per share, more than 80% below the Class Period high.

INVESTOR ALERT: Xponential Fitness, Inc. (NYSE: XPOF) Investors With Losses of More Than $100,000 Encouraged to Seek Appointment as Lead Plaintiff – April 9, 2024 Deadline

Retrieved on: 
Tuesday, April 2, 2024
Bloomberg Businessweek, District court, SAN, News, Retirement, Court, Cryptocurrency

This action is pending in the United States District Court for the Central District of California.

Key Points: 
  • This action is pending in the United States District Court for the Central District of California.
  • If you wish to serve as a lead plaintiff in this class action, we can help you petition the Court by the April 9, 2024 deadline.
  • Until a class is certified, you are not represented by counsel unless you retain one.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

LUNA INNOVATIONS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Luna Innovations, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 2, 2024
Telephone, District court, LUNA, Bank statement, Person, P.C, Court, Luna Innovations, Cryptocurrency

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Luna Innovations, Inc. (“Luna Innovations” or the “Company”) (NASDAQ: LUNA) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Luna Innovations securities between August 11, 2023 and March 25, 2024, both dates inclusive (the “Class Period”).

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Luna Innovations, Inc. (“Luna Innovations” or the “Company”) (NASDAQ: LUNA) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Luna Innovations securities between August 11, 2023 and March 25, 2024, both dates inclusive (the “Class Period”).
  • Investors have until May 31, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • There is no cost or obligation to you.

Kessler Topaz Meltzer & Check, LLP Notifies The Chemours Company Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Ethics, CC, CFO, District court, Lead, LLP, Controller, COPY, Form 10-K, Senior, Adjustment, Collection, Court, Audit committee, Cryptocurrency

RADNOR, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company ( NYSE: CC ) (“Chemours” or the “Company”) on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”).

Key Points: 
  • RADNOR, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company ( NYSE: CC ) (“Chemours” or the “Company”) on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”).
  • This action, captioned Taylor Jr. v. The Chemours Company, et al., Case No.
  • Important Deadline Reminder: Investors who purchased or otherwise acquired Chemours common stock during the Class Period may, no later than May 20, 2024, move the Court to serve as lead plaintiff for the class.
  • Kessler Topaz Meltzer & Check, LLP encourages Chemours investors who have suffered significant losses to contact the firm directly to acquire more information.

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Retrieved on: 
Monday, April 1, 2024
Research, Court of Chancery, Notifiable disease, Ovarian cancer, JAMS, Prejudice, District court, Inflammation, Patient, Sale, News, G&A, University, Cancer, Trial of the century, Bank statement, Loss, Complaint, Pancreatic cancer, Patent, Probability, Court, Pharmaceutical industry

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
  • Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, “These are exciting times at HCW Biologics.
  • Revenues: Revenues for the fourth quarters ended December 31, 2022 and 2023 were $1.3 million and $1.3 million, respectively.
  • Net loss: Net loss for the fourth quarters ended December 31, 2022 and 2023 were $5.4 million and $10.7 million, respectively.